Ben L. writes, "I don't know if you listened to the recent Dendreon ( DNDN) quarterly conference call, but what was shared has obviously caused some concern amongst the investment community. The stock has been dropping since the call even though I have not seen any analyst downgrades for Dendreon.
Aaron A. writes, "I see Allos Therapeutics ( ALTH) finally got word of their scheduled FDA panel meeting to review pralatrexate on Sept. 2, which lines up well for final FDA decision of this fast-tracked drug by the Sept. 24 PDUFA date. You still positive on Allos? Where does it trade if it gets approval? Citi has a $15 target. JMP Securities a $20 target, Needham sees $12. What do you say?"
Moving onward to an email from Bill H. "Do you have an update on YM Biosciences ( TICKER) in light of the license grant from the Office of Foreign Assets Control to further develop Nimotuzumab?"
Jean M. writes, "May I make a suggestion? I love it when you show the hate mail you receive. I get a good laugh at how stupid most of the people writing in are. How about an article of your Top 10 hate emails? Oh wait, I just discovered that if I want to see stupid people, I can go to the Google and Yahoo! message boards! Anyway, thanks for all the interesting reading that you provide, especially the fact that you come up with new ideas and new ways of looking at things that others do not." Snap!